Publications by authors named "Pau Gilabert"

Claim this Profile
F
Frequency and Effectiveness of Dose Escalation and De-Escalation of Biologic Therapy in Inflammatory Bowel Disease: The RAINBOW-IBD Study of ENEIDA.
Cristina Rubín de Célix, Elena Ricart, M Dolores Martín-Arranz, Ruth de Francisco, Francisco Javier García-Alonso, Pau Gilabert

Aliment Pharmacol Ther· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative Study on the Management and Outcomes of Postoperative Crohn's Disease in Older Patients: Data From the ENEIDA Registry.
Míriam Mañosa, Margalida Calafat, Elena Ricart, Pilar Nos, Eva Iglesias, Pau Gilabert

United European Gastroenterol J· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: New fecal bacterial signature for colorectal cancer screening reduces the fecal immunochemical test false-positive rate in a screening population.
Marta Malagón, Sara Ramió-Pujol, Marta Serrano, Joan Amoedo, Lia Oliver, Pau Gilabert

PLoS One· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ileal Predominance in Crohn's Disease Is Associated With Increased Intestinal Surgery and Biological Therapy Use, With Lower Treatment Persistence.
Antonio Giordano, Isabel Pérez-Martínez, Javier P Gisbert, Elena Ricart, María Dolores Martín-Arranz, Pau Gilabert

Am J Gastroenterol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Outcomes of Biological Therapy in Crohn's Disease Complicated With Internal Fistulizing Disease: BIOSCOPE Study From GETECCU.
Manuel Barreiro-de Acosta, Agnès Fernández-Clotet, Francisco Mesonero, Francisco Javier García-Alonso, María José Casanova, Pau Gilabert

Am J Gastroenterol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness and safety of ustekinumab in bio-naïve Crohn's disease patients: a multicentre observational retrospective study.
Valdés Delgado Teresa, Olmedo Martín Rául, Iborra Marisa, Herrera de Guisé Claudia, Fuentes-Valenzuela Esteban, Gilabert Álvarez Pau

Therap Adv Gastroenterol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Presentation, Management, and Evolution of Lymphomas in Patients with Inflammatory Bowel Disease: An ENEIDA Registry Study.
Ivan Guerra, Luis Bujanda, Miriam Mañosa, Isabel Pérez-Martínez, María José Casanova, Pau Gilabert

Cancers (Basel)· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk Factors for COVID-19 in Inflammatory Bowel Disease: A National, ENEIDA-Based Case-Control Study (COVID-19-EII).
Yamile Zabana, Ignacio Marín-Jiménez, Iago Rodríguez-Lago, Isabel Vera, María Dolores Martín-Arranz, Pau Gilabert

J Clin Med· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry.
Yamile Zabana, Ignacio Marín-Jiménez, Iago Rodríguez-Lago, Isabel Vera, María Dolores Martín-Arranz, Pau Gilabert

J Clin Med· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RAID Prediction: Pilot Study of Fecal Microbial Signature With Capacity to Predict Response to Anti-TNF Treatment.
David Busquets, Lia Oliver, Joan Amoedo, Sara Ramió-Pujol, Marta Malagón, Pau Gilabert

Inflamm Bowel Dis· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New fecal bacterial signature for colorectal cancer screening reduces the fecal immunochemical test false-positive rate in a screening population.
Marta Malagón, Sara Ramió-Pujol, Marta Serrano, Joan Amoedo, Lia Oliver, Pau Gilabert

PLoS One· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure.
Qian Chen, Celia Perales, María Eugenia Soria, Damir García-Cehic, Josep Gregori, Pau Gilabert

Antiviral Res· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The use of faecal immunochemical testing in the decision-making process for the endoscopic investigation of iron deficiency anaemia.
Lorena Rodriguez-Alonso, Francisco Rodriguez-Moranta, Alexandra Ruiz-Cerulla, Claudia Arajol, Katja Serra, Pau Gilabert

Clin Chem Lab Med· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reduction of faecal immunochemical test false-positive results using a signature based on faecal bacterial markers.
Marta Malagón, Sara Ramió-Pujol, Marta Serrano, Mariona Serra-Pagès, Joan Amoedo, Pau Gilabert

Aliment Pharmacol Ther· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Proton pump inhibitors reduce the accuracy of faecal immunochemical test for detecting advanced colorectal neoplasia in symptomatic patients.
Lorena Rodriguez-Alonso, Francisco Rodriguez-Moranta, Claudia Arajol, Pau Gilabert, Katja Serra

PLoS One· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis